Genetic variations in CYP2B6 and CYP2C19 genes and their effects on antidepressant actions and adverse effects of sertraline in patients with majordepressive disorder

BACKGROUND: Selective serotonin reuptake inhibitor (SSRI), sertraline, is one of the most frequently prescribed antidepressants used to treat Major Depressive Disorder (MDD) and utilized as the first-line treatment for depression. Sertraline is primarily metabolized by CYP2B6 and CYP2C19, which are identified as highly polymorphic. Genetic variation in CYP2C19 and CYP2B6 results in altered enzymatic activity, ultimately resulting in interindividual differences in the sertraline therapeutic efficacy andenhancing the danger of contrary sertraline reactions in patients with MDD.METHODS: A prospective cohort research was designed to find the link between genetic polymorphism in (CYP2B6 and CYP2C19) and the efficacy and/or adverse effects of sertraline in patients with MDD. A convenient sampling strategy was used in the study. The 17-item Hamilton Depression Rating Scale (HDRS) was used to evaluate the therapeutic response of sertraline, and the LUNSER scale was used to evaluate side effects that sertraline may have caused.RESULTS: In our study, non-responder phenomenon was 53.33%. No statistically significant difference was found in genotype frequencies between the responders and nonresponders. The genotype frequencies of the SNPs showed no statistically significant difference between the responders and nonresponders. However, a statistical significant difference was found in HDRS mean scores between respondersand non-responders in the 12th week but no statistical significant difference was found in LUNSERS mean scores between responders and nonresponders.CONCLUSION: In conclusion, our data suggest that genetic polymorphisms in CYP2B6 and CYP2C19 genes (21563C>T) and (681G>A), respectively, do not significantly influence sertraline efficacy and safety profile.